
Sixteen United States Senators and 30 members of the House of Representatives recently wrote to the Centers for Medicare & Medicaid Services urging the agency to finalize its proposed guidance on how Medicare prescription drug plan sponsors report pharmacy price concessions, often referred to as direct and indirect remuneration fees, to provide more accurate information to beneficiaries, pharmacies and the federal government.








